( this measure has not been amended since it was introduced .
the summary has been expanded because action occurred on the measure . )
better empowerment now to enhance framework and improve treatments act of 2017 or the benefit act of 2017 ( sec. 2 ) this bill amends the federal food , drug , and cosmetic act to require the food and drug administration ( fda ) to consider patient-focused drug development data , such as patient preferences , patient-reported outcomes , and patient experiences , as part of the risk-benefit assessment of new drugs .
following approval of a drug , the fda must include a description of how this information was considered in its statement of patient experience .